1 December 2010 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
In order to answer the question “what research remains to be done?” we review the current state of the art in pharmaceutical aerosol deposition modeling and explore possible in vivo– in vitro correlations (IVIVC) linking drug deposition in the human lung to predictions made using in vitro physical airway models and in silico computer models. The use of physical replicas of portions of the respiratory tract is considered, alongside the advantages and disadvantages of the different imaging methods used to obtain their dimensions. The use of airway replicas to determine drug deposition in vitro is discussed and compared with the predictions from different empirical curve fits to long-standing in vivo deposition data for monodisperse aerosols. The use of improved computational models and three-dimensional computational fluid dynamics (CFD) to predict aerosol deposition within the respiratory tract is examined. CFD's ability to predict both drug deposition from pharmaceutical aerosol sprays and powder behavior in dry powder inhalers is examined; both were highlighted as important areas for future research. Although the authors note the abilities of current in vitro and in silico methods to predict in vivo data, a number of limitations remain. These include our present inability to either image or replicate all but the most proximal airways in sufficient spatial and temporal detail to allow full capture of the fluid and aerosol mechanics in these regions. In addition, the highly complex microscale behavior of aerosols within inhalers and the respiratory tract places extreme computational demands on in silico methods. When the complexity of variations in respiratory tract geometry is associated with additional factors such as breathing pattern, age, disease state, postural position, and patient-device interaction are all considered, it is clear that further research is required before the prediction of all aspects of inhaled pharmaceutical aerosol deposition is possible.
1 June 2013 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Background: A new in vitro test method for dry powder inhalers (DPIs) was recently found to be predictive of the published in vivo results for Budelin Novolizer. The present study was intended to assess the method's robustness by evaluating correlations between average drug deposition in vitro and in vivo from five different DPIs. Methods: In vitro drug deposition from five marketed DPIs was assessed in a realistic physical airway model of a “medium” sized adult in an experimental setup that allowed deposition to be characterized regionally for carefully selected simulated air flow rate versus time profiles. The DPIs studied were Spiriva® HandiHaler®, Relenza® Diskhaler®, Salbutamol Easyhaler®, Pulmicort® Turbuhaler®, and Foradil® Aerolizer®. In vitro regional deposition results were compared with those reported in the literature in order to create in vitro–in vivo correlations (IVIVCs) for each inhaler. Results: Mean percent total lung deposition (TLD±SD) in vitro for Spiriva HandiHaler, Relenza Diskhaler, Salbutamol Easyhaler, Pulmicort Turbuhaler, and Foradil Aerolizer were 17.3±1.2, 22.6±1.1, 29.0±1.1, 28.0±3.0, and 21.7±1.2, respectively. These results showed excellent agreement with reported in vivo values, with absolute prediction errors in TLD of ≤2% for all DPIs except Relenza Diskhaler. Similarly, in vitro mouth–throat and device deposition results were stoichiometrically comparable to those reported in vivo for all DPIs except Relenza Diskhaler and Turbuhaler. Inspection of the scintigraphy studies for Relenza Diskhaler and Turbohaler revealed possible problems with powder labeling and result interpretation in their in vivo clinical assessments. Conclusions: A characteristic physical airway model representing a medium-sized adult, when coupled to carefully chosen characteristic inhalation maneuvers used in the clinic, produced results that correlated with regional drug deposition estimates from scintigraphy across a group of different DPIs.
1 December 2004 in Proceedings of the American Thoracic Society
New techniques for delivery of drugs by inhalation are discussed in this article. Devices that promise to improve the efficiency of lung delivery are described along with some of the regulatory challenges faced by their development scientists. Although high delivery efficiencies are possible, such devices are expensive to develop and may only be feasible in the event that they are partnered with drugs whose therapeutic and economic value is truly enhanced by the effort invested in the process. Appropriate devices must also be selected after paying careful attention to the physicochemical and dosing demands associated with the drug substance to be inhaled. Even newly launched commercial products display large variations in dose delivery to the lung, in spite of increased global efforts to regulate and ensure the uniformity of delivered doses and their aerosol size distributions; this because of variations in the inspiratory maneuvers used by patients and the lack of control exercised over these maneuvers by most new inhalers. Sophisticated electromechanical techniques are discussed as possible ways of overcoming some of the common difficulties associated with ensuring reproducibility of dose and drug delivery to the lung.
8 October 2015 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
RDRenishkumar R. Delvadia
Background: The amount of drug aerosol from an inhaler that can pass through an in vitro model of the mouth and throat (MT) during a realistic breath or inhalation flow rate vs. time profile (IP) is designated the total lung dose in vitro , or
TLD
in vitro
. This article describes a clinical study that enabled us to recommend a general method of selecting IPs for use with powder inhalers of known airflow resistance (R) provided subjects followed written instructions either alone or in combination with formal training. Methods: In a drug-free clinical trial, inhaler-naïve, nonsmoking healthy adult human volunteers were screened for normal pulmonary function. IPs were collected from each volunteer inhaling through different air flow resistances after different levels of training. IPs were analyzed to determine the distribution of inhalation variables across the population and their dependence on training and airflow resistance. Results: Equations for IP simulation are presented that describe the data including confidence limits at each resistance and training condition. Realistic IPs at upper (90%), median (50%), and lower (10%) confidence limits were functions of R and training. Peak inspiratory flow rates (PIFR) were inversely proportional to R so that if R was assigned, values for PIFR could be calculated. The time of PIFR, T PIFR , and the total inhaled volume (V) were unrelated to R, but dependent on training. Once R was assigned for a powder inhaler to be tested, a range of simulated IPs could be generated for the different training scenarios. Values for flow rate acceleration and depth of inspiration could also be varied within the population limits of T PIFR and V. Conclusions: The use of simulated IPs, in concert with realistic in vitro testing, should improve the DPI design process and the confidence with which clinical testing may be initiated for a chosen device.
1 February 2002 in Journal of Pharmaceutical Sciences
1 October 2017 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
RDRenishkumar R. Delvadia
Background: The dose and aerodynamic particle size distribution (APSD) of drug aerosols' exiting models of the mouth and throat (MT) during a realistic inhalation profile (IP) may be estimated in vitro and designated Total Lung Dose, TLDin vitro, and APSDTLDin vitro, respectively. These aerosol characteristics likely define the drug's regional distribution in the lung. Methods: A general method was evaluated to enable the simultaneous determination of TLDin vitro and APSDTLDin vitro for budesonide aerosols' exiting small, medium and large VCU-MT models. Following calibration of the modified next generation pharmaceutical impactor (NGI) at 140 L/min, variations in aerosol dose and size exiting MT were determined from Budelin® Novolizer® across the IPs reported by Newman et al., who assessed drug deposition from this inhaler by scintigraphy. Results: Values for TLDin vitro from the test inhaler determined by the general method were found to be statistically comparable to those using a filter capture method. Using new stage cutoffs determined by calibration of the modified NGI at 140 L/min, APSDTLDin vitro profiles and mass median aerodynamic diameters at the MT exit (MMADTLDin vitro) were determined as functions of MT geometric size across Newman's IPs. The range of mean values (n ≥ 5) for TLDin vitro and MMADTLDin vitro for this inhaler extended from 6.2 to 103.0 μg (3.1%–51.5% of label claim) and from 1.7 to 3.6 μm, respectively. Conclusions: The method enables reliable determination of TLDin vitro and APSDTLDin vitro for aerosols likely to enter the trachea of test subjects in the clinic. By simulating realistic IPs and testing in different MT models, the effects of major variables on TLDin vitro and APSDTLDin vitro may be studied using the general method described in this study.